Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open-label Phase IIa Study Evaluating Quantified Bone Scan Response Following Treatment With Radium-223 Dichloride Alone or in Combination With Abiraterone Acetate or Enzalutamide in Subjects With Castration-resistant Prostate Cancer Who Have Bone Metastases

NCT02034552 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02034552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02034552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open-label Phase IIa Study Evaluating Quantified Bone Scan Response Following Treatment With Radium-223 Dichloride Alone or in Combination With Abiraterone Acetate or Enzalutamide in Subjects With Castration-resistant Prostate Cancer Who Have Bone Metastases
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
March 7, 2014
Completion date
June 26, 2018
Enrollment
68 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms